Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day
Community focuses on elevating awareness of the burden of FCS and impact on daily living
BOSTON, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness Day on November 2, 2018. FCS Awareness Day, which will occur annually on the first Friday in November, is a global observance to build broader awareness of the challenges associated with the disease.
“We are very proud to recognize the first global FCS Awareness Day along with all members of the FCS community around the world. As we advance our research and understanding of FCS, this historic event is another symbol of how far the community has come in recent years,” said Molly Harper, VP, Global Head & Franchise General Manager of Akcea Therapeutics.
Familial chylomicronemia syndrome (FCS) is an ultra-rare, devastating hereditary disease that causes unpredictable and potentially fatal acute pancreatitis, chronic complications due to permanent organ damage, and a severe impact on daily living. It is estimated that there are between 3,000 to 5,000 people living with FCS worldwide.
“With the creation of an FCS Awareness Day, patients, caregivers and families have a new platform and opportunity to share their stories and to help others learn about FCS,” said Alan Gilstrap, executive director, advocacy and policy at Akcea. “We have had the privilege of hearing from so many patients about their experiences. Their stories highlight the continuing challenges that FCS presents every day and we are continuing our commitment to the lipid and FCS communities. Our hope is that more patients and caregivers can connect with each other, as we now know there are several benefits that connectivity can provide in FCS.”
In July, Akcea announced results of the CONNECT study providing many first-time assessments of the benefits of patient connectivity in FCS. Results showed a range of benefits when patients and caregivers connect in person or online, including improved perceptions of overall health, disease outlook, motivation to take care of health and emotional well-being. The study also found that connecting with other patients can positively impact the quality of life for people living with FCS.
“As part of the global FCS community, we are so pleased to recognize the first FCS Awareness Day, which is a great reflection of our mission to build awareness and provide support while also advocating for research that will lead to a treatment for FCS,” said Lindsey Sutton, co-president of The FCS Foundation. “As someone who knows personally how devastating FCS can be, I hope this day serves as a way to educate others about the symptoms and burden of the disease. Living with FCS can often feel isolating, and our goal is to help all patients realize that they are not alone in dealing with the challenges brought on by FCS.”
The FCS Foundation, along with members of the global FCS Community, invite patients, caregivers, clinicians, friends and family to participate on social media using hashtags #FCSAWARENESSDAY, #ACTIONFCS and #LIVINGWITHFCS.
FCS is an ultra-rare disease caused by impaired function of the enzyme lipoprotein lipase (LPL) and characterized by severe hypertriglyceridemia (>880mg/dL) and a risk of unpredictable and potentially fatal acute pancreatitis. Because of limited LPL function, people with FCS cannot breakdown chylomicrons, lipoprotein particles that are 90% triglycerides. In addition to pancreatitis, FCS patients are at risk of chronic complications due to permanent organ damage, including chronic pancreatitis and pancreatogenic diabetes. They can experience daily symptoms including abdominal pain, generalized fatigue and impaired cognitions that affect their ability to work. People with FCS also report major emotional and psychosocial effects including anxiety, social withdrawal, depression and brain fog. There is no effective therapy for FCS currently available. Additional information on FCS is available at www.fcsfocus.com, and through the FCS Foundation at http://www.livingwithfcs.org and the LPLD Alliance at www.lpldalliance.org. For a full list of organizations supporting the FCS community worldwide, please click here.
ABOUT AKCEA THERAPEUTICS, INC.
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including TEGSEDITM (inotersen), WAYLIVRATM (volanesorsen), AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. TEGSEDI is approved in the U.S., E.U. and Canada. WAYLIVRA is under regulatory review for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Boston, Massachusetts. Additional information about Akcea is available at www.akceatx.com.
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in its quarterly report on Form 10-Q and other documents, which are on file with the SEC.
In this press release, unless the context requires otherwise, “Akcea,” “Company,” “we,” “our,” and “us” refers to Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™, TEGSEDI™ and WAYLIVRA™ are trademarks of Akcea Therapeutics, Inc.
Akcea Investor Contact:
Vice President of Communications and Investor Relations
Akcea Media Contact:
Berry & Company
T: 212 253-8881
Berry & Company
T: 212 253-8881
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Algeco Enters Into Definitive Agreement to Sell Target Lodging14.11.2018 00:59 | Pressemelding
LONDON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (“Algeco Investments”, and together with its subsidiaries, “Algeco”), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that certain of its subsidiaries have entered into a definitive agreement (the “Stock Purchase Agreement”) with Platinum Eagle Acquisition Corp., a publicly traded special purpose acquisition company (“PEAC”), to sell the Algeco Group’s North American remote accommodations business, Target Lodging, to Target Lodging Holdings Corp. (“Holdco”), a newly-formed subsidiary of PEAC (the “Transaction”). Simultaneously to the Target Lodging sale, TDR Capital LLP will be selling its Signor Holdings business to PEAC as well. Andrew Tyler, CEO Algeco: “We are very excited about the sale of Target Lodging to Platinum Eagle Acquisition Corp. This sale captures significant value for Algeco and allows Algeco to continu
This is a test from GlobeNewswire13.11.2018 23:54 | Pressemelding
LONDON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Senior Director, Global Head of GlobeNewswire Media Relations Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or David Didier Lislet Manager, GlobeNewswire Media Relations, EMEA Phone: +33 185 341 347
ELS Educational Services, Inc. Wins English Language School Award for Sixth Consecutive Year13.11.2018 23:20 | Pressemelding
ELS Educational Services, Inc. won the award for English Language School – USA at the UED Agency Awards of Turkey. This is the sixth consecutive year ELS has won the award. Princeton, New Jersey, Nov. 13, 2018 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE ELS Educational Services, Inc. won the award for English Language School – USA at the UED Agency Awards of Turkey. This is the sixth consecutive year ELS has won the award. The UED Agency Awards is the first competition of its kind that recognizes excellence among language schools and service providers in Turkey. Institutions are nominated then voted on by UED Member Agencies, who are the leaders of the international education consultancy sector in Turkey. “The ELS brand is stronger than ever in Turkey,” said Osman Akyuz, Director of Recruitment and Agent Support in Turkey. “We provide the best academic English in great locations and we have the most experienced instructors.” ELS was presented the award at a banquet at the Divan Otel / Ta
Doc re. GE Files Form 8-K13.11.2018 17:30 | Pressemelding
FAIRFIELD, Conn., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-k November 13, 2018 On November 13, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to RNS. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. http://www.rns-pdf.londonstockexchange.com/rns/2365H_1-2018-11-13.pdf CONTACT: GE Jennifer Erickson +001 646 682 5620 firstname.lastname@example.org This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visi
CloudGenix Named a Finalist in the 2018 CRN® Tech Innovator Awards13.11.2018 17:00 | Pressemelding
Company’s AppFabric Recognized in the 2018 Enterprise Networking Category SAN JOSE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- CloudGenix announced today that CRN , ® a brand of The Channel Company, has been recognized as a finalist in the 2018 CRN Tech Innovator Awards. These annual awards honor standout hardware, software, and services that are moving the IT industry forward. In compiling the 2018 Tech Innovator Award list, CRN editors evaluated 300 products across 34 technology categories using several criteria, including technological advancements, uniqueness of features and potential to help solution providers solve end users' IT challenges. CloudGenix’s AppFabric took top honors in the Enterprise Networking category. CloudGenix AppFabric is a revolutionary software-defined wide area networking (SD-WAN) platform that allows businesses to integrate cloud and SaaS applications, create a secure application-defined fabric across any WAN transport, reduce operational cost and complexity
Atico Reports Reserves of 119 Million Pounds of Copper at the El Roble Mine13.11.2018 15:51 | Pressemelding
VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) is pleased to announce the release of an updated NI 43-101 mineral resource and reserve estimate for the El Roble Mine located in Colombia. El Roble is currently in production at a rate of 850tpd and production guidance for the year is 20 million pounds of copper along with 9,850 ounces of gold in 2018. For the first three quarters of 2018, El Roble has produced 16 million pounds of copper and 8,400 ounces of gold or over 80% and 85% of annual forecast production for copper and gold respectively. “Our infill and mine vicinity exploration drilling at El Roble mine has been successful in replenishing mined resources since 2013. The maiden resource study at El Roble mine of 1.5 million tonnes of inferred resource has grown to 1.8 million tonnes of measured and indicated resources, while also having mined over 1 million tonnes of high-grade ore during
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom